原发性肝癌分子靶向治疗基础与临床研究进展

Progress in basic and clinical research on molecular targeted therapy for primary hepatic carcinoma

原发性肝癌是世界上发病率第2的癌症,已成为我国癌症相关死亡原因中最常见的原因之一,对病人及患者家庭带来巨大的病痛和经济负担.传统的治疗方法迄今并未取得令人满意的效果,人们逐渐将目光转向有着精确性、不良反应小等诸多优点的靶向药物治疗.已有研究证实靶向药物索拉非尼的上市能改善原发性肝癌患者生存期,开启肿瘤靶向治疗的新纪元,近年来,肝癌的分子靶向治疗成为研究热点,随着研究的深入,已发现多种新型分子靶向药物能改善中晚期肝癌患者的预后.本文旨在阐述原发性肝癌分子靶向治疗基础与临床研究的最新进展.

As the second most common cancer in the world, primary liver cancer has become one of the most common causes of cancer-related death in China, causing great pain and financial burden to patients and their families. Traditional treatment methods have not achieved satisfactory results so far, and people are gradually turning their attention to targeted drug therapy, which has many advantages, such as accuracy and little adverse reactions. Previous studies have shown that the introduction of targeted drug sorafenib can improve the survival of patients with primary liver cancer and open a new era of tumor targeted therapy. In recent years, molecular targeted therapy for liver cancer has become a research hotspot. A variety of new molecular targeted drugs have been found to be able to improve the prognosis of patients with advanced liver cancer. The purpose of this article is to review the progress in basic and clinical research on molecular targeted therapy for primary hepatic carcinoma.